Email this article Relationship between Hedgehog Signaling Pathway and Drug Resistance of Poorly Differentiated Gliomas
- Authors: Cherepanov S.A.1,2, Grinenko N.F.2, Antonova O.M.2, Kurapov P.B.1, Shepeleva I.I.1,2, Chekhonin V.P.1,2
-
Affiliations:
- N. I. Pirogov National Research Medical University, Ministry of Health of the Russian Federation
- V. P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
- Issue: Vol 164, No 3 (2018)
- Pages: 356-361
- Section: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/239597
- DOI: https://doi.org/10.1007/s10517-018-3989-x
- ID: 239597
Cite item
Open Access
Access granted
Subscription Access
Abstract
The effects of Hedgehog signaling inhibitor (cyclopamine) and activator (Shh) on drug resistance of U251-MG human glioma cells and human astrocyte culture to cisplatin, temozolomide, and doxorubicin were studied. Cyclopamine and Shh modified the drug resistance of U251-MG cells but not of human astrocytes. Experiments with cyclopamine, Shh, and chemical drugs can contribute to detection of the mechanisms of signaling effects on the drug resistance processes, while the experimental data can serve as one of the criteria for choosing individual chemotherapy for patients.
About the authors
S. A. Cherepanov
N. I. Pirogov National Research Medical University, Ministry of Health of the Russian Federation; V. P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
Author for correspondence.
Email: cherep-rsmu@yandex.ru
Russian Federation, Moscow; Moscow
N. F. Grinenko
V. P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
Email: cherep-rsmu@yandex.ru
Russian Federation, Moscow
O. M. Antonova
V. P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
Email: cherep-rsmu@yandex.ru
Russian Federation, Moscow
P. B. Kurapov
N. I. Pirogov National Research Medical University, Ministry of Health of the Russian Federation
Email: cherep-rsmu@yandex.ru
Russian Federation, Moscow
I. I. Shepeleva
N. I. Pirogov National Research Medical University, Ministry of Health of the Russian Federation; V. P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
Email: cherep-rsmu@yandex.ru
Russian Federation, Moscow; Moscow
V. P. Chekhonin
N. I. Pirogov National Research Medical University, Ministry of Health of the Russian Federation; V. P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation
Email: cherep-rsmu@yandex.ru
Russian Federation, Moscow; Moscow
Supplementary files
